Japan· JP-4291472D1026
サシツズマブ ゴビテカン（遺伝子組換え）
A medicinal product containing サシツズマブ ゴビテカン（遺伝子組換え）, registered in Japan by ギリアド・サイエンシズ, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- サシツズマブ ゴビテカン（遺伝子組換え）
- Manufacturer
- ギリアド・サイエンシズ
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
サシツズマブ ゴビテカン（遺伝子組換え） in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTRODELVYGilead Sciences, Inc.
- SpainTRODELVY 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONGilead Sciences Ireland Unlimited Company
- FinlandTrodelvyOrifarm Oy
- CzechiaTRODELVYGilead Sciences Ireland UC, Carrigtohill
- FranceTRODELVY 200 mg, poudre pour solution à diluer pour perfusionGILEAD SCIENCES IRELAND UC (IRLANDE)
- BelgiumTrodelvy 200 mgGilead Sciences Ireland UC
- IrelandTrodelvy 200 mg powder for concentrate for solution for infusionGilead Sciences Ireland UC
- IcelandTrodelvyGilead Sciences Ireland UC*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Trodelvy
- Liechtenstein · Trodelvy
- Norway · Trodelvy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/efecbea5-d938-4939-b7dc-ca3ac1affb9c GET /v1/drugs/efecbea5-d938-4939-b7dc-ca3ac1affb9c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２００ｍｇ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291472D1026",
"category": "注射薬",
"price_yen": 187195,
"generic_name": "サシツズマブ ゴビテカン（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about サシツズマブ ゴビテカン（遺伝子組換え）.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.